Evidence map›Paper›PMID 40697410›Full record

ArticleiScience2025

A potent phenylalkylamine disrupts mycobacterial membrane bioenergetics and augments bactericidal activity of bedaquiline.

Zheng Yen Phua, Ming Li, Azhar Ali, Cedric Cheng Sheng Cheong, Kai Jie Goh, Marcus Yi Kang Seto, Amos Shi Ying Ng, Jickky Palmae Sarathy, Boon Cher Goh, Mei Lin Go and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zheng Yen PhuaDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Ming LiDepartment of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, 14 Medical Dr, Singapore 117599, Singapore.
Azhar AliCancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
Cedric Cheng Sheng CheongDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Kai Jie GohDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Marcus Yi Kang SetoDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Amos Shi Ying NgDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.
Jickky Palmae SarathyCenter for Discovery and Innovation, Hackensack Meridien Health, 111 Ideation Way, Nutley, NJ 07110, USA.
Boon Cher GohCancer Science Institute of Singapore, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599, Singapore.
Mei Lin GoDepartment of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
Wai Keung ChuiDepartment of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
Thomas DickCenter for Discovery and Innovation, Hackensack Meridien Health, 111 Ideation Way, Nutley, NJ 07110, USA.
Yulin LamDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore.

Funding

Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0M
NIAID NIH HHS R01 AI132374
6 · The paper itself

Abstract

Clinically efficacious combination therapies capable of impeding resistance are widely sought for the treatment of mycobacterial infections. Here, we described structural modifications of the phenylalkylamine scaffold of verapamil to give an analog with more than 10-fold greater growth inhibitory activity than verapamil against

Indexed as

Biological sciencesChemistryEnergy engineering

Identifiers

PMID40697410
PMCPMC12281142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.